Fulzerasib
Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905) .[1][2].
Product Specifications
CAS Number
[2641747-54-6]
Product Name Alternative
IBI351; GFH925
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fulzerasib.html
Purity
99.60
Solubility
DMSO : 116.67 mg/mL (ultrasonic)
Smiles
O=C(C=C)N1CCN2C(C3=C(N4C5=C(C(C)C)N=CC=C5C)N=C(C6=C(O)C=CC=C6F)C(Cl)=C3)=C(N(C)C([C@@]2([H])C1)=O)C4=O
Molecular Formula
C32H30ClFN6O4
Molecular Weight
617.07
References & Citations
[1]Rafael Rosell, et al. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC) . Crit Rev Oncol Hematol. 2024 Mar:195:104228.|[2]Vanesa Gregorc, et al. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib. Free access.June 05, 2024
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
K-Ras
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
